Treatment of Behçet's Disease with Inflammatory Eye Disease Affecting the Posterior Segment

Clinical Scenario

This protocol applies to patients with Behçet's syndrome who have inflammatory eye disease involving the posterior segment — a serious ocular manifestation requiring prompt, structured systemic treatment. Posterior segment involvement in Behçet's syndrome carries a significant risk to vision and demands a defined treatment approach developed in close collaboration with ophthalmology.

Treatment Approach

Systemic immunosuppressive therapy is central to management. The evidence-based regimen involves specific agents from established drug classes — the full sequence, combination rules, and criteria for agent selection are in the structured protocol.

Goal: Remission of ocular inflammation

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/annrheumdis-2018-213225

Any patient with BS and inflammatory eye disease affecting the posterior segment should be on a treatment regime such as azathioprine (level of evidence: IB; strength of recommendation: A), cyclosporine-A (level of evidence: IB; strength of recommendation: A), interferon-alpha (level of evidence: IIA; strength of recommendation: B) or monoclonal anti-TNF antibodies (level of evidence: IIA; strength of recommendation: B).
Systemic glucocorticoids should be used only in combination with azathioprine or other systemic immunosuppressives.
Management of uveitis of BS requires close collaboration with ophthalmologists with the ultimate aim of inducing and maintaining remission.

View source ↗